CAJ | 학술논문

目的评价89SrCl2治疗乳腺癌骨转移的临床疗效,及其血液学毒副作用.方法 51例患者接受89SrCl2治疗,静脉注射剂量为2.22 MBq/kg体重,观察治疗前后止痛效果,病灶变化和外周血细胞变化.结果患者疼痛完全缓解率为37.7%(17/45),总缓解率为84.4%.病灶治疗有效率为62.7%(32/51).治疗后1个月白细胞和血小板减少者分别为76.5%和62.7%.3个月后大多数患者经治疗血象恢复到正常.结论 89SrCl2可安全、有效地治疗乳腺癌骨转移患者的疼痛,并对其生活质量有所改善.
목적 평개89SrCl2치료유선암골전이적림상료효,급기혈액학독부작용.방법 51례환자접수89SrCl2치료,정맥주사제량위2.22 MBq/kg체중,관찰치료전후지통효과,병조변화화외주혈세포변화.결과 환자동통완전완해솔위37.7%(17/45),총완해솔위84.4%.병조치료유효솔위62.7%(32/51).치료후1개월백세포화혈소판감소자분별위76.5%화62.7%.3개월후대다수환자경치료혈상회복도정상.결론 89SrCl2가안전、유효지치료유선암골전이환자적동통,병대기생활질량유소개선.
Objective To evaluate the clinical effect of 89SrCh2 as a palliative therapy for breast caneer patients with bone metastasis,and to observe the hematological toxieity induced by 89SrCl2 treatment.Methods 89SrCl2 dosage was 2.22 MBq/kg each time by intravenous for 51 patients.The analog scale.the cancer size and the hematological toxicity of 89SrCl2 treatment were observed.Results 17 patients(37.7%)among 45 patients became free of pain.The total pain relief rate was 84.4%.The response rate of metastatic sites was 62.7%. Approximately 76.5%of patients experienced neutmpenia one month after theatment,whereas 62.7%of patients experienced thromboeytopenia.But the most of the patients could recover to the normal level 3 months after treatment.Conclusions 89SrCl2 is an effective and safe way for the pain relief and the life quality improvement in breast cancer patients with bone metastasis.